By otakuyassine3@gmail.com 
Bruker Co. (NASDAQ:BRKR – Get Free Report)’s stock price dropped 5.3% on Wednesday . The company traded as low as $57.11 and last traded at $58.02. Approximately 805,182 shares changed hands during trading, a decline of 34% from the average daily volume of 1,224,903 shares. The stock had previously closed at $61.26.
Analyst Ratings Changes
A number of brokerages have weighed in on BRKR. The Goldman Sachs Group upgraded shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price target on the stock in a report on Thursday, December 5th. Citigroup lowered their price target on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. TD Cowen cut their price objective on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a report on Wednesday, November 6th. UBS Group began coverage on Bruker in a report on Tuesday, December 10th. They set a “neutral” rating and a $66.00 target price for the company. Finally, Bank of America raised their price target on shares of Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a report on Friday, December 13th. Six analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Bruker presently has a consensus rating of “Moderate Buy” and a consensus target price of $74.45.
Bruker Stock Down 3.6 %
The firm’s 50 day moving average price is $57.81 and its two-hundred day moving average price is $61.70. The firm has a market capitalization of $8.62 billion, a PE ratio of 27.35, a P/E/G ratio of 3.55 and a beta of 1.17. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24.
Bruker (NASDAQ:BRKR – Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a net margin of 9.41% and a return on equity of 21.52%. The firm had revenue of $864.40 million during the quarter, compared to analysts’ expectations of $866.46 million. During the same period in the previous year, the company earned $0.74 earnings per share. The business’s quarterly revenue was up 16.4% on a year-over-year basis. As a group, research analysts forecast that Bruker Co. will post 2.39 EPS for the current fiscal year.
Bruker Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Monday, December 2nd were paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.35%. The ex-dividend date of this dividend was Monday, December 2nd. Bruker’s dividend payout ratio (DPR) is currently 9.62%.
Insider Buying and Selling
In other news, CEO Frank H. Laukien purchased 100,000 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was acquired at an average cost of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the purchase, the chief executive officer now owns 38,439,563 shares of the company’s stock, valued at approximately $1,927,359,688.82. This trade represents a 0.26 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 28.30% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the company. UMB Bank n.a. lifted its stake in Bruker by 37.5% during the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock worth $53,000 after purchasing an additional 248 shares during the last quarter. CGN Advisors LLC bought a new position in shares of Bruker in the 4th quarter worth about $1,273,000. Merit Financial Group LLC bought a new position in shares of Bruker in the 4th quarter worth about $300,000. Assenagon Asset Management S.A. boosted its stake in Bruker by 11.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 115,508 shares of the medical research company’s stock valued at $6,771,000 after acquiring an additional 11,860 shares during the period. Finally, Eagle Bay Advisors LLC grew its stake in Bruker by 2,324.1% during the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock worth $41,000 after buying an additional 674 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.
About Bruker
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Featured Articles
Receive News & Ratings for Bruker Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bruker and related companies with MarketBeat.com’s FREE daily email newsletter.